Private Equity

Wendel Investment Managers' affiliates raise over €11 billion, validating the firm's strategic pivot and defying a tough private capital market.

As Moelis & Co. prepares to report its 2025 results, investors are watching to see if the firm capitalized on a record year for dealmaking.

MIT economist Andrew Lo joins the Global Coalition for Adaptive Research, bringing Wall Street strategies to revolutionize clinical trials for rare diseases.

Amid a national shortage of over 7M homes, National Equity Fund's record 2025 investments and innovative financing created 14,200 affordable units.

Guggenheim Investments' new $250M vehicle, backed by LGT Capital Partners, highlights the strategic depth and enduring allure of the private credit market.

Fresh off its 'Fierce 15' win, Recludix Pharma and its billion-dollar Sanofi pact take the spotlight with a novel oral drug for inflammatory diseases.

A new alliance pairs Relation's 'Lab-in-the-Loop' AI with Deerfield's investment might, aiming to fast-track novel drugs for intractable diseases.

Lazard Asset Management creates a new CIO role, appointing Eric Van Nostrand to unify its global investment platform amid fierce industry competition.

A landmark $1.2M order for its advanced LineaDNA validates the firm's biotech arm, but can scientific success balance its new, volatile crypto strategy?

With promising new drugs for obesity and liver disease, clinical-stage MetaVia steps into the spotlight at a key industry conference, facing giants and high hopes.

Chile's state oil firm, ENAP, sees massive investor demand for its debt buyback, a move that strengthens its balance sheet for a major energy transition.

Oak Hill Advisors' record fundraise underscores a major shift in corporate finance, as private credit becomes the go-to capital source for large-cap firms.

Following stellar clinical data, Terns Pharmaceuticals' upsized $650M offering signals massive investor confidence and funds its push to disrupt the CML market.